![pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg)
The Major Pharmaceutical Preparations industry reporters start to interpret the third quarter of 2022 earnings. Now those reporters monitor operating shortfall of $-1.533378 millions, from the Immix Biopharma Inc , as it has not specified any revenue thus far, for the own July to September 30 2022 quarter.
The emerging growth company has not declared the revenue thus far, but to set recent conduct into a frame of reference. It is supported by correlating with corporate effort through the third quarter of 2021, where the Immix Biopharma Inc reported an operating shortfall of $-1.352014 millions.
While the Immix Biopharma Inc is still emerging the revenue streams, by some means the company managed to curb the diminishing Returns in the fiscal third quarter of 2022 to $-1.535 millions, from the $-24.384 millions, in the third quarter of 2021.
Immix Biopharma Inc is expected to report next financial recent numbers on March 27, 2023.